

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

### MTA for avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Final appraisal determination

(when no ACD was issued)

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The committee noted the comment received during scoping from the company that produces lusutrombopag that if [lusutrombopag] is recommended it may improve access to further treatments and reduce inequalities for certain social and religious groups by providing an alternative treatment option to platelet transfusions. The committee agreed with the conclusions reached at the scoping stage that this was not an equality issue because its decision to recommend lusutrombopag will not make it harder for these groups to access treatment.
---

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Similar comments on the use of platelet transfusions by some social and religious groups to during scoping were raised. The committee's conclusions were as above.
--

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The committee considered that it was possible that the donating population of platelets would represent a different ethnic mix than the population with chronic liver disease and thrombocytopenia and this may make it harder to match donor platelets with the recipient if matched platelets were needed. The committee agreed that this was not an equalities issue because its recommendations did not make it harder for any ethnic group to access lusutrombopag.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, section 3.16

**Approved by Associate Director (name):** Nicole Elliott

**Date:** 31/10/2019